Effects of dietary sodium and magnesium on cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats

Hypertension

Volumn 29, Issue 3, 1997, Pages 822-827

  Mervaala, Eero M A ^a   Pere, Anna Kaisa ^b   Lindgren, Leena ^b   Laakso, Juha ^b   Teräväinen, Terttu Liisa ^b   Karjala, Kirsi ^b   Vapaatalo, Heikki ^b   Ahonen, Juhani ^b   Karppanen, Heikki ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

calcium; cyclosporine; hypertrophy, left ventricular; magnesium; proteinuria; rats, spontaneously hypertensive; sodium

Indexed keywords

CALCIUM; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MAGNESIUM; SODIUM;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CREATININE CLEARANCE; DIET SUPPLEMENTATION; DRUG INDUCED DISEASE; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; SODIUM INTAKE; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0031032839     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.3.822     Document Type: Article

References (40)

1. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med. 1986;314:1219-1225.
2. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;45:953-1040.
3. Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RAF, Burnett JC. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc. 1994;69:1182-1193.
4. Wong NLM, Dirks JH. Cyclosporin-induced hypomagnesaemia and renal magnesium wasting in rats. Clin Sci. 1988;75:509-514.
5. Barton CH, Vaziri ND, Mina-Araghi S, Crosby S, Seo I. Effects of cyclosporine on magnesium metabolism in rats. J Lab Clin Med. 1989;114:232-236.
6. Nozue T, Kobayashi A, Kodama T, Uemasu F, Endoh H, Sako A, Takagi Y. Pathogenesis of cyclosporine-induced hypomagnesemia. J Pediatr. 1992;120:638-640.
7. Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet. 1984;2:1116-1120.
8. June CH, Thompson CB, Kennedy MS, Nims J, Thomas ED. Profound hypomagnesemia and renal magnesium wasting associated with the use of cyclosporine for marrow transplantation. Transplantation. 1985;39:620-624.
9. Millane TA, Jennison SH, Mann JM, Holt DW, McKenna WJ, Camm AJ. Myocardial magnesium depletion associated with prolonged hypomagnesemia: a longitudinal study in heart transplant recipients. J Am Coll Cardiol. 1992;20:806-812.
10. Millane T, Wilson AJ, Patel MK, Jennison SH, Holt DW, Murday AJ, Camm AJ. Mitochondrial calcium deposition in association with cyclosporine therapy and myocardial magnesium depletion: a serial histologic study in heart transplant recipients. J Heart Lung Transplant. 1994;13:473-480.
11. Dyer AR, Shipley M, Elliot P. Urinary electrolyte excretion in 24 hours and blood pressure in the INTERSALT study, I: estimates of reliability. Am J Epidemiol. 1994;139:927-939.
12. Dyer AR, Elliot P, Shipley M. Urinary electrolyte excretion in 24 hours and blood pressure in the INTERSALT study, II: estimates of electrolyte-blood pressure associations corrected for regression dilution bias. Am J Epidemiol. 1994;139:940-951.
13. Elliot P, Stamler J, Nichols R, Dyer AR, Stamler R, Kesteloot H, Marmot M. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Br Med J. 1996;312:1249-1253.
14. Mervaala EMA, Teräväinen T-L, Pere A-K, Lindgren L, Laakso J, Karjala K, Vapaatalo H, Ahonen J, Karppanen H. Dietary salt aggravates cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats: protection by oral magnesium supplementation. Contrib Nephrol. 1996;119:121-124.
15. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
16. Laakso JT, Tikkanen H, Michelsson J-E. Element concentrations in normal and immobilization-induced necrotic rabbit muscles. Trace Elem Med. 1991;8:34-42.
17. Tobian L. Salt and hypertension: lessons from animal models that relate to human hypertension. Hypertension. 1991;17(suppl I): I-52-I-58.
18. Louis WJ, Tabei R, Spector S. Effects of sodium intake on inherited hypertension in the rat. Lancet. 1971;2:1283-1286.
19. Aoki K, Yamori Y, Ooshima A, Okamoto K. Effects of high or low sodium intake in spontaneously hypertensive rats. Jpn Circ J. 1972;36:539-545.
20. Mervaala EMA, Himberg J-J, Laakso J, Tuomainen P, Karppanen H. Beneficial effects of a potassium- and magnesium-enriched salt alternative. Hypertension. 1992;19:535-540.
21. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med. 1988;85:134-138.
22. Lustig S, Stem N, Eggena P, Tuck ML, Lee DBN. Effect of cyclosporin on blood pressure and renin-aldosterone axis in rats. Am J Physiol. 1987;253:H1596-H1600.
23. Roullet J-P, Xue H, McCarron DA, Holcomb S, Bennett WM. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest. 1994;93:2244-2250.
24. Elzinga LW, Rosen S, Bennett WM. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake. J Am Soc Nephrol. 1993;4:214-221.
25. Gerkens JF, Bhagwandeen SB, Dosen PJ, Smith AJ. The effect of salt intake on cyclosporine-induced impairment of renal function in rats. Transplantation. 1984;38:412-417.
26. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED. Renin, angiotensin and aldosterone system in the pathogenesis and management of hypertensive vascular disease. Am J Med. 1972; 52:633-652.
27. + feeding in stroke-prone hypertensive rats. Hypertension. 1990;15:318-326.
28. Mason J. Pharmacology of cyclosporine (Sandimmune), VII: pathophysiology and toxicology of cyclosporine in humans and animals. Pharmacol Rev. 1989;42:423-434.
29. Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH. On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. J Hypertens. 1988;6:763-777.
30. Campese V. Salt sensitivity in hypertension: renal and cardiovascular implications. Hypertension. 1994;23:531-550.
31. Mitchell KD, Braam B, Navar LG. Hypertensinogenic mechanisms mediated by renal actions of renin-angiotensin system. Hypertension. 1992;19(suppl I):I-18-I-27.
32. Frohlich E, Apstein C, Chobanian A, Devereux R, Dustan H, Dzau V, Fauad-Tarazi F, Horan M, Marcus M, Massie B, Pfefer M, Re R, Roccella E, Savage D, Shub C. The heart in hypertension. N Engl J Med. 1992;327:998-1008.
33. Schmieder R, Messerli F, Garagavlia G, Nunez B. Dietary salt intake: a determinant of cardiac involvement in essential hypertension. Circulation. 1988;78:951-956.
34. Yuan B, Leenen F. Dietary sodium intake and left ventricular hypertrophy in normotensive rats. Am J Physiol. 1991;261:H1397-H1401.
35. Mervaala EMA, Laakso J, Vapaatalo H, Karppanen H. Effects of enalapril and hydrochlorothiazide on the salt-induced cardiac and renal hypertrophy in normotensive rats. Naunyn Schmiedebergs Arch Pharmacol. 1994;350:416-425.
36. Altura BM, Altura BT. New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system, II: experimental aspects. Magnesium. 1985;4:245-271.
37. Woods KL. Possible pharmacological actions of magnesium in acute myocardial infarction. Br J Clin Pharmacol. 1991;32:3-10.
38. Teo KK, Yusuf S. Role of magnesium in reducing mortality in acute myocardial infarction: a review of the evidence. Drugs. 1993;46: 347-359.
39. Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. Calcium, a neglected key factor in hypertension and arteriosclerosis: experimental vasoprotection with calcium antagonists or ACE inhibitors. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press Publishers; 1990:471-509.
40. Koroshetz WJ, Moskowitz MA. Emerging treatments tor stroke in humans. Trends Pharmacol Sci. 1996;17:227-233.